Memo to Windsor/Essex Health Care Providers
July 13, 2018
Health Canada recently issued a warning regarding specific lots of generic valsartan that has been adulterated with a known carcinogen (NDMA).
As such, all affected stock must be pulled from pharmacies and provider sample inventories. Due to the wide spread nature of this recall, switching to unaffected valsartan stock may prove to be difficult as other valsartan products have already been listed as backordered and are unavailable for purchase.
Providers are encouraged to work with their patients’ pharmacists in order to identify affected patients and switch patients to an appropriate angiotensin receptor blocker (ARB). Close monitoring of blood pressure, potassium, and renal function may be required during this transition period.
Also, attached is a memo that will be posted on various websites and shared with the media to be published for our community.
We will attempt to provide updates on this recall. However, please visit the Health Canada website for update information.